Mark Schoenebaum Recent News
Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger
Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call
AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors
Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
With Bristol-Myers Trial Stopped Early, 'What's Next?'
Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key
Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact
ISI Says AstraZeneca Needs To 'Speak Up For Increased Bid'
Top Financial Tweets From February 11, 2014
Analysts Comment on Merck's Hep C Regiment Advances
ISI Group Believes That Genzyme Corporation (GENZ) Could Jump to $80
ISI Group Is Bullish On AMLN, HGSI, GENZ And DNDN
Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN)